statistiche ricercatore

Continente	#
AS - Asia	594
NA - Nord America	552
EU - Europa	397
SA - Sud America	55
Continente sconosciuto - Info sul continente non disponibili	25
AF - Africa	17
OC - Oceania	3
Totale	1.643

Nazione	#
US - Stati Uniti d'America	522
SG - Singapore	247
RU - Federazione Russa	168
VN - Vietnam	109
CN - Cina	107
IT - Italia	89
FR - Francia	69
IN - India	45
BR - Brasile	44
HK - Hong Kong	39
FI - Finlandia	19
DE - Germania	18
CA - Canada	17
CI - Costa d'Avorio	12
IE - Irlanda	12
JP - Giappone	9
TR - Turchia	6
MX - Messico	5
BD - Bangladesh	4
GB - Regno Unito	4
IQ - Iraq	4
KR - Corea	4
NL - Olanda	4
PH - Filippine	4
AR - Argentina	3
AU - Australia	3
CZ - Repubblica Ceca	3
DO - Repubblica Dominicana	3
EC - Ecuador	3
IL - Israele	3
UA - Ucraina	3
BZ - Belize	2
CL - Cile	2
ID - Indonesia	2
PK - Pakistan	2
PL - Polonia	2
SY - Repubblica araba siriana	2
UZ - Uzbekistan	2
ZA - Sudafrica	2
AT - Austria	1
AZ - Azerbaigian	1
CO - Colombia	1
EG - Egitto	1
ES - Italia	1
GA - Gabon	1
GR - Grecia	1
GY - Guiana	1
HN - Honduras	1
JM - Giamaica	1
JO - Giordania	1
LT - Lituania	1
NP - Nepal	1
PA - Panama	1
PE - Perù	1
SE - Svezia	1
SK - Slovacchia (Repubblica Slovacca)	1
TH - Thailandia	1
TN - Tunisia	1
TW - Taiwan	1
Totale	1.618

Nome	#
A novel in silico framework to improve MHC-I epitopes and break the tolerance to melanoma	243
Oncolytic adenovirus loaded with L-carnosine as a drug delivery system for cancer therapy.	169
Oncolytic adenovirus loaded with L-carnosine as novel strategy to enhance the antitumor activity	166
The Anti-Proliferative Effect of L-Carnosine Correlates with a Decreased Expression of Hypoxia Inducible Factor 1 alpha in Human Colon Cancer Cells.	140
L-Carnosine and Human Colon Cancer	132
The evolution of adenoviral vectors through genetic and chemical surface modifications	126
Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model	117
A novel in silico framework to improve MHC-I epitopes and break the tolerance to melanoma (vol 6, e1319028, 2017)	115
Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model	112
Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity	110
Isoflavones in aglycone solution enhance ultraviolet B-induced DNA damage repair efficiency.	107
Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma	106
Totale	1.643

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	68	0	0	0	2	0	1	4	3	14	0	18	26
2022/2023	157	11	11	1	7	33	27	0	21	18	2	8	18
2023/2024	96	13	25	7	1	10	5	2	16	0	1	7	9
2024/2025	357	18	10	1	2	23	29	37	21	21	28	140	27
2025/2026	733	67	43	79	68	145	29	76	38	90	72	18	8
2026/2027	48	9	39	0	0	0	0	0	0	0	0	0	0
Totale													1.643